$LNTH News
Last published 2d ago
- 2d agoLNTHPharmaLogic to Acquire Lantheus' CDMO Business and Springfield, New Jersey Manufacturing FacilityPR NewswirePharmaLogic Holdings Corp. ("PharmaLogic" or the "Company"), the only independent contract development and manufacturing organization (CDMO) of...
- 6d agoLNTHLantheus Holdings, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 6d agoLNTHLantheus Welcomes CMS CY27 Final Rule Advancing Access to Diagnostic RadiopharmaceuticalsGlobeNewswireBEDFORD, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians
- 6d agoLNTHLantheus Reports Third Quarter 2026 Financial ResultsGlobeNewswireWorldwide revenue of $389.9 million in the third quarter of 2026GAAP fully diluted earnings per share of $0.33, compared to $0.41 in the third quarter of 2025Adjusted fully diluted earnings per share of $1.68, compared
- 1w agoLNTHLantheus Announces Presentation of Data at the 2026 Clinical Trials on Alzheimer’s Disease Annual MeetingGlobeNewswireBEDFORD, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease
- 2mo agoLNTHLantheus Announces FDA Approval of TAUKLARIFY™ (Florquinitau F 18 Injection), an F18-Labeled Tau PET Imaging Agent for Alzheimer’s DiseaseGlobeNewswireBEDFORD, Mass., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians
- 3mo agoLNTHLantheus Reports Second Quarter 2026 Financial ResultsGlobeNewswireWorldwide revenue of $388.2 million in the second quarter of 2026GAAP fully diluted earnings per share of $1.11, compared to $1.12 in the second quarter of 2025Adjusted fully diluted earnings per share of $1.55,
- 3mo agoLNTHCurium Announces Definitive Agreement to Merge with LantheusGlobeNewswireStrategic transaction would bring Curium's theranostics portfolio and global manufacturing platform together with Lantheus’ complementary U.S. radiodiagnostics business Total transaction consideration to Lantheus
- 3mo agoLNTHLantheus to Host Second Quarter 2026 Earnings Conference Call and Webcast on August 6, 2026, at 8:00 a.m. Eastern TimeGlobeNewswireBEDFORD, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the "Company") (NASDAQ:LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday, August 6,
- 3mo agoLNTHRadioMedix Appoints Brian A. Markison to Board of DirectorsGlobeNewswireHOUSTON, July 15, 2026 (GLOBE NEWSWIRE) -- RadioMedix, Inc., a clinical-stage biotechnology company focused on innovative targeted radiopharmaceuticals for diagnosis, monitoring, and cancer therapy, today announced
- 4mo agoLNTHLantheus Receives Complete Response Letter from FDA for LNTH-2501 (Ga 68 edotreotide)GlobeNewswireBEDFORD, Mass., June 26, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus" or "Company") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to
- 5mo agoLNTHLantheus to Present at the Goldman Sachs 47th Annual Global Healthcare ConferenceGlobeNewswireBEDFORD, Mass., June 03, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company dedicated to helping clinicians Find, Fight, and
- 5mo agoLNTHLantheus' LNTH-2513 (18F-GP1) PET/CT Awarded SNMMI's Image of the YearGlobeNewswireBEDFORD, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow
- 5mo agoLNTHLantheus to Present at the William Blair 46th Annual Growth Stock ConferenceGlobeNewswireBEDFORD, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company dedicated to helping clinicians Find, Fight, and
- 5mo agoLNTHLantheus Highlights New Radiodiagnostic Data at the 2026 SNMMI Annual MeetingGlobeNewswireBEDFORD, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease
- 5mo agoLNTHLantheus Announces Presentation of Data at the 2026 American Society of Clinical Oncology (ASCO) Annual MeetingGlobeNewswireBEDFORD, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease
- 6mo agoLNTHQ1 2026 Lantheus Earnings Conference CallLANTHEUS HOLDINGS INCEarnings Call TranscriptsGood morning. Welcome to Lanthea's first quarter 2026 conference call. All lines have been placed on mute. This call is being recorded and a replay will be available in the investor section of the company's website appro
- 6mo agoLNTHLantheus Reports First Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswireStrong start to the year with worldwide revenue of $377.3 million in the first quarter 2026GAAP fully diluted earnings per share of $1.80, compared to $1.02 in the first quarter of 2025Adjusted fully diluted earnings per
- 6mo agoLNTHLantheus to Host First Quarter 2026 Earnings Conference Call and Webcast on May 7, 2026, at 8:00 a.m. Eastern TimeGlobeNewswireBEDFORD, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the "Company") (NASDAQ:LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday, May 7, 2026, to
- 8mo agoLNTHLantheus Announces FDA Approval of PYLARIFY TruVu™ (piflufolastat F 18) InjectionGlobeNewswireNew formulation of its widely-used U.S. market-leading PSMA PET imaging agent combines thediagnostic performance of PYLARIFY® (piflufolastat F 18) with the potential for larger batches and greater patient
- 8mo agoLNTHLantheus Receives FDA Tentative Approval for Lutetium Lu 177 Dotatate (PNT2003), Radioequivalent to LUTATHERA®GlobeNewswireBEDFORD, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight
- 8mo agoLNTHQ4 2025 Lantheus Earnings Conference CallLANTHEUS HOLDINGS INCEarnings Call TranscriptsGood morning. Welcome to Lanthea's fourth quarter and full year 2025 conference call. All lines have been placed on mute. This call is being recorded and a replay will be available in the investors section of the company
- 8mo agoLNTHLantheus Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateGlobeNewswireWorldwide revenue of $406.8 million and $1.54 billion for the fourth quarter and full year 2025GAAP fully diluted earnings per share of $0.82 and $3.41 for the fourth quarter and full year 2025Adjusted fully diluted
- 8mo agoLNTHLantheus to Present at March 2026 Investor ConferencesGlobeNewswireBEDFORD, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company dedicated to helping clinicians Find, Fight, and
- 9mo agoLNTHLantheus to Host Fourth Quarter and Full Year 2025 Earnings Conference Call and Webcast on February 26, 2026, at 8:00 a.m. Eastern TimeGlobeNewswireBEDFORD, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the "Company") (NASDAQ:LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday, February 26, 2026, to
- 10mo agoLNTHLantheus Announces Closing of SPECT Business Sale to SHINE TechnologiesGlobeNewswireBEDFORD, Mass., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company dedicated to helping clinicians Find, Fight, and
- 11mo agoLNTHLantheus to Present Florbetaben F 18 Data at CTAD 2025GlobeNewswireBEDFORD, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease
- 1y agoLNTHLantheus Holdings, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before November 10, 2025 to Discuss Your Rights - LNTHPR NewswireThe Gross Law Firm issues the following notice to shareholders of Lantheus Holdings, Inc. (NASDAQ: LNTH). Shareholders who purchased shares of LNTH...
- 1y agoLNTHLantheus Reports Third Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswireRecorded third quarter 2025 worldwide revenue of $384.0 million, GAAP fully diluted earnings per share of $0.41, adjusted fully diluted earnings per share of $1.27 and free cash flow of $94.7 millionSeparately announced
- 1y agoLNTHLantheus Announces Leadership Transition PlanGlobeNewswireBrian Markison to Retire as Chief Executive Officer; Board Conducting Search for Next CEO Continued Execution of Company's Strategy to be Led by Prior CEO Mary Anne Heino as Executive Chairperson BEDFORD, Mass., Nov.
- 1y agoLNTHLNTH INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of LantheusGlobeNewswireFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $10,000 In Lantheus To Contact Him Directly To Discuss Their Options If you suffered losses
- 1y agoLNTHThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of November 10, 2025 in Lantheus Holdings, Inc. Lawsuit – LNTHGlobeNewswireNEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Lantheus Holdings, Inc. (NASDAQ:LNTH). Shareholders who purchased shares of LNTH during the class period
- 1y agoLNTHSHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of LantheusGlobeNewswireFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Lantheus To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in
- 1y agoLNTHShareholders of Lantheus Holdings, Inc. Should Contact The Gross Law Firm Before November 10, 2025 to Discuss Your Rights - LNTHPR NewswireThe Gross Law Firm issues the following notice to shareholders of Lantheus Holdings, Inc. (NASDAQ: LNTH). Shareholders who purchased shares of LNTH...
- 1y agoLNTHLantheus Announces FDA Grants PDUFA Date for LNTH-2501 (Ga 68 edotreotide), a PET Diagnostic Imaging Kit Targeting Somatostatin Receptor-Positive (SSTR+) Neuroendocrine Tumors (NETs)GlobeNewswireBEDFORD, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease
- 1y agoLNTHSHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of LantheusPR NewswireFaruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Lantheus Holdings, Inc. ("Lantheus" or the...
- 1y agoLNTHLantheus Announces FDA Acceptance of New Drug Application for MK-6240, a PET Imaging Agent Targeting Tau in Alzheimer's DiseaseGlobeNewswireBEDFORD, Mass., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease
- 1y agoLNTHINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of LantheusPR NewswireFaruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Lantheus Holdings, Inc. ("Lantheus" or the...
- 1y agoLNTHShareholders of Lantheus Holdings, Inc. Should Contact The Gross Law Firm Before November 10, 2025 to Discuss Your Rights - LNTHPR NewswireThe Gross Law Firm issues the following notice to shareholders of Lantheus Holdings, Inc. (NASDAQ: LNTH). Shareholders who purchased shares of LNTH...
- 1y agoLNTHLantheus to Host Third Quarter 2025 Earnings Conference Call and Webcast on November 6, 2025, at 8:00 a.m. Eastern TimeGlobeNewswireBEDFORD, Mass., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the "Company") (NASDAQ:LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday, November 6, 2025, to
- 1y agoNVDABFLYLNTHRDNTInvestors Turn to AI-Driven Imaging Firms Targeting High-Growth Breast Cancer MarketPR NewswireArtificial intelligence (AI) continues to transform healthcare innovation, with medical imaging emerging as one of its most promising frontiers. In...
- 1y agoLNTHSHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of LantheusPR NewswireFaruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Lantheus Holdings, Inc. ("Lantheus" or the...
- 1y agoLNTHThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of November 10, 2025 in Lantheus Holdings, Inc. Lawsuit - LNTHPR NewswireThe Gross Law Firm issues the following notice to shareholders of Lantheus Holdings, Inc. (NASDAQ: LNTH). Shareholders who purchased shares of LNTH...
- 1y agoLNTHLNTH INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of LantheusGlobeNewswireFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Lantheus To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in
- 1y agoLNTHSHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of LantheusPR NewswireFaruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Lantheus Holdings, Inc. ("Lantheus" or the...
- 1y agoLNTHINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of LantheusGlobeNewswireFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Lantheus To Contact Him Directly To Discuss Their Options If you suffered losses in Lantheus between
- 1y agoLNTHThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of November 10, 2025 in Lantheus Lawsuit - LNTHPR NewswireThe Gross Law Firm issues the following notice to shareholders of Lantheus Holdings, Inc. (NASDAQ: LNTH). Shareholders who purchased shares of LNTH...
- 1y agoGEHCLNTHLantheus and GE HealthCare Announce Exclusive Licensing Agreement for Prostate Cancer Imaging Agent PYLARIFY® (Piflufolastat F 18) in JapanGlobeNewswireBEDFORD, Mass. and CHICAGO and TOKYO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (NASDAQ:LNTH) and GE HealthCare (NASDAQ:GEHC) today announced an exclusive licensing agreement for GE HealthCare to
- 1y agoLNTHSHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of LantheusGlobeNewswireFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Lantheus To Contact Him Directly To Discuss Their Options If you suffered losses
- 1y agoLNTHSHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of LantheusPR NewswireFaruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Lantheus Holdings, Inc. ("Lantheus" or the...